Gastrointestinal

Primary biliary cholangitis: diagnosis and management

Clinical Overview and When to Suspect Primary Biliary Cholangitis

— Predominantly affects middle-aged women (female:male ratio ~9:1)

— Peak incidence age 40–60 years

— Prevalence higher in Northern European populations; positive family history in ~5%

— Strong association with other autoimmune conditions (Sjögren, Hashimoto, Raynaud, scleroderma/CREST, celiac)

— Loss of immune tolerance to PDC-E2 (pyruvate dehydrogenase complex) on biliary epithelial cells

— Granulomatous destruction of interlobular bile ducts → ductopenia → cholestasis

— Environmental triggers (UTIs with E. coli, xenobiotics in cosmetics, smoking) in genetically susceptible hosts

— Middle-aged woman with unexplained alkaline phosphatase elevation (>1.5× ULN) for >6 months

— Fatigue and pruritus disproportionate to other findings

— Coexisting autoimmune disease (especially Sjögren or autoimmune thyroiditis)

— Incidental cholestatic LFTs on routine screening or perioperative labs

— Xanthelasma, hyperlipidemia, or osteoporosis in a non-classical demographic

— Early diagnosis + ursodeoxycholic acid (UDCA) dramatically alters long-term survival

— Inadequate biochemical response at 12 months drives second-line decisions

— Long-term surveillance for HCC, varices, and metabolic bone disease defines outpatient care

Board pearl: Any woman 40–60 with isolated ALP elevation, normal imaging, and pruritus should have AMA (anti-mitochondrial antibody) ordered before invasive testing — it is the cornerstone of noninvasive diagnosis and obviates biopsy in most patients.

Definition: Primary biliary cholangitis (PBC, formerly primary biliary cirrhosis) is a chronic, autoimmune, cholestatic liver disease characterized by progressive destruction of small intrahepatic bile ducts, leading to cholestasis, fibrosis, and ultimately cirrhosis if untreated.

Epidemiology:

Pathogenesis pearls:

When to suspect PBC — high-yield Step 3 triggers:

Why it matters on Step 3:

Presentation Patterns and Key History

— ~50–60% diagnosed incidentally from elevated ALP on routine labs

— Disease may be silent for years; biochemical abnormalities precede symptoms

— Fatigue (up to 80%): non-specific, often disabling, poorly correlated with disease stage, not responsive to UDCA

— Pruritus (20–70%): worse at night and with heat/wool contact, often generalized, can precede jaundice by years; mediated by bile acids, autotaxin/LPA, and endogenous opioids

— Jaundice, dark urine, pale stools (suggests advanced ductopenia)

— Steatorrhea and fat-soluble vitamin deficiencies (A, D, E, K)

— Hyperpigmentation (melanin deposition, not jaundice)

— Xanthelasma and tendinous xanthomas (hypercholesterolemia)

— Bone pain or fragility fracture (hepatic osteodystrophy)

— Decompensation: ascites, variceal bleed, hepatic encephalopathy

— Duration of fatigue and pruritus; nocturnal scratching, sleep disruption

— Family history of PBC or autoimmune disease (10× risk in first-degree relatives)

— Sicca symptoms (dry eyes/mouth — Sjögren overlaps in 30–50%)

— Raynaud, dysphagia, sclerodactyly (CREST overlap)

— Alcohol, hepatotoxic medications, herbals, occupational exposures (to exclude alternatives)

— Prior cholecystectomy or biliary surgery (to assess for secondary cholestasis)

— Vaccination status (HAV/HBV), since chronic liver disease patients need protection

— Rapidly rising bilirubin without ALP elevation → think obstruction

— Marked transaminitis (>5× ULN) → consider overlap with autoimmune hepatitis

— Male predominance, IBD, beaded ducts on imaging → think PSC

Step 3 management: When a 52-year-old woman reports months of nocturnal itching and unexplained fatigue, order ALP, GGT, AST/ALT, bilirubin, AMA, and abdominal ultrasound before dermatology referral — pruritus is the workup gateway, not the endpoint.

The classic asymptomatic presentation (most common today):

Symptomatic presentation — the two cardinal complaints:

Late/advanced presentation clues:

Targeted history — must-ask items:

Red flags pointing away from pure PBC:

Physical Exam Findings and Systemic Assessment

— Patients with significant biochemical disease may appear well

— Document baseline weight, BMI, and vitals for longitudinal tracking

— Excoriations from chronic pruritus, often on extensor surfaces and back

— Hyperpigmentation — diffuse, melanin-based, often mistaken for tan

— Xanthelasma (periorbital) and tendinous xanthomas (Achilles, extensor tendons) from cholestatic hypercholesterolemia

— Jaundice — late finding; sclera first at bilirubin >2.5 mg/dL

— Dry mucous membranes if coexisting Sjögren

— Hepatomegaly in ~25%; firm, non-tender

— Splenomegaly suggests portal hypertension (advanced disease)

— Ascites, caput medusae → decompensated cirrhosis

— Right upper quadrant tenderness is uncommon — its presence should prompt evaluation for cholangitis or stones

— Kyphosis, height loss, or vertebral tenderness → screen for osteoporosis

— Proximal muscle weakness (consider vitamin D deficiency, sarcopenia)

— Asterixis, altered mentation → hepatic encephalopathy in advanced disease

— Peripheral neuropathy from vitamin E deficiency (rare)

— Generally preserved until decompensation

— In cirrhotic stage: hyperdynamic circulation (warm extremities, bounding pulses, wide pulse pressure)

— Screen for hepatopulmonary syndrome (platypnea, orthodeoxia, clubbing) and portopulmonary hypertension (loud P2, RV heave) in advanced cases

— Sclerodactyly, telangiectasias, calcinosis cutis → CREST/PBC overlap

— Parotid enlargement, dry tongue → Sjögren overlap

Key distinction: Hyperpigmentation in PBC is melanin-driven and present before jaundice; conversely, scleral icterus reflects conjugated hyperbilirubinemia and signals late-stage ductopenic disease with worse prognosis — a major prognostic inflection point on the GLOBE and UK-PBC scores.

Early-stage exam — frequently normal, which is a board trap:

Skin and mucous membranes:

Abdominal exam:

Musculoskeletal/bone:

Neurologic:

Cardiopulmonary and hemodynamic assessment:

Overlap-syndrome exam clues:

Diagnostic Workup — Initial Labs, Imaging, and Biomarkers

— Alkaline phosphatase (ALP): elevated, often 3–10× ULN — the dominant abnormality

— GGT: elevated in parallel, confirms hepatic (not bony) ALP source

— AST/ALT: mildly elevated (typically <5× ULN); markedly elevated suggests AIH overlap

— Bilirubin: normal early; rises with advanced disease and is a key prognostic marker

— Albumin and INR: normal until decompensation

— Hypercholesterolemia common (often striking LDL or lipoprotein-X)

— Despite elevated cholesterol, cardiovascular risk is not proportionally increased in non-cirrhotic PBC

— Check TSH (autoimmune thyroid overlap), HbA1c, vitamin D

— Anti-mitochondrial antibody (AMA), especially M2 subtype: ~95% sensitivity, >95% specificity; titer ≥1:40

— PBC-specific ANAs: anti-sp100 and anti-gp210 — useful when AMA-negative; gp210 confers worse prognosis

— Total IgM characteristically elevated

— Check ANA, ASMA, anti-LKM, IgG to evaluate for AIH overlap

— Right upper quadrant ultrasound is the mandatory first imaging test in any cholestatic patient

— In PBC: normal ducts, possibly hepatomegaly or splenomegaly; no biliary dilation

— Dilated ducts → pursue MRCP/ERCP for stones, strictures, malignancy, or PSC

— HBsAg, anti-HCV, HIV — needed before immunosuppression and for vaccination decisions

— Transient elastography (FibroScan) is preferred for staging — values >10 kPa suggest advanced fibrosis

— APRI and FIB-4 are less validated in PBC but provide trend data

Board pearl: The diagnostic triad establishing PBC without biopsy = (1) ALP >1.5× ULN for ≥6 months, (2) positive AMA (≥1:40) or PBC-specific ANA, and (3) compatible/exclusionary imaging. Two of three suffice; meeting all three lets you skip biopsy in the great majority of patients.

Cornerstone biochemical pattern: cholestatic injury

Lipid and metabolic panel:

Immunology — the diagnostic backbone:

Imaging — to exclude obstruction:

Hepatitis screen:

Noninvasive fibrosis assessment:

Diagnostic Workup — Confirmatory and Advanced Studies

— AMA-negative patients with cholestatic labs and suspected PBC

— Suspected overlap syndrome with autoimmune hepatitis (disproportionate ALT/AST, high IgG, positive ASMA/anti-LKM)

— Suspicion of coexisting condition (NAFLD, drug-induced injury, sarcoidosis)

— Discordant clinical/biochemical picture or atypical demographics (young male, very rapid progression)

— Florid duct lesion: granulomatous, lymphocytic destruction of interlobular bile ducts

— Four Ludwig stages: (1) portal inflammation, (2) periportal interface activity, (3) septal fibrosis, (4) cirrhosis

— Ductopenia (loss of >50% of bile ducts in portal tracts) is pathognomonic in context

— MRCP if any imaging suggests ductal abnormality — required to rule out PSC, especially in men or those with IBD

— CT abdomen for HCC surveillance once cirrhosis established (or US q6 months ± AFP)

— Vibration-controlled transient elastography (VCTE): noninvasive, repeatable; thresholds approximately — <8 kPa (minimal), 8–10 (significant), >10 (advanced), >15 (cirrhosis)

— UK-PBC risk score and GLOBE score: validated long-term mortality/transplant-free survival predictors using bilirubin, ALP, albumin, platelets, age

— Endoscopy (EGD) for variceal screening when platelets <150k or elastography >20 kPa

— DEXA scan at diagnosis, then every 2–3 years

— Fat-soluble vitamin levels (A, D, E, K/PT) particularly when bilirubin elevated

Step 3 management: In an AMA-negative cholestatic woman, do not stop at "idiopathic" — order anti-sp100 and anti-gp210, then proceed to liver biopsy; ~5% of true PBC patients are AMA-negative and biopsy clinches the diagnosis, unlocking life-prolonging UDCA therapy.

When to perform liver biopsy (not routinely required):

Histopathology — the classic finding:

Advanced imaging:

Fibrosis staging and prognostic tools:

Bone density and nutritional studies:

Evaluating overlap syndromes — "Paris criteria" for PBC–AIH overlap: 2 of 3 PBC features + 2 of 3 AIH features (ALT >5× ULN, IgG >2× ULN or +ASMA, moderate/severe interface hepatitis on biopsy).

Risk Stratification and First-Line Management Logic

— Slow histologic progression and delay cirrhosis/transplant

— Achieve biochemical response — the single best modifiable prognostic marker

— Manage symptoms (pruritus, fatigue, sicca, bone disease)

— Surveil for and prevent complications (HCC, varices, fractures)

— High-risk features: male sex, age <45 at diagnosis, bilirubin >ULN, albumin <LLN, platelets <150k, cirrhosis on imaging/elastography, anti-gp210 positivity, AMA-negative phenotype

— Use GLOBE and UK-PBC scores to estimate transplant-free survival; these guide intensity of follow-up

— Paris II criteria (early disease): ALP and AST ≤1.5× ULN and normal bilirubin

— POISE criteria (used in obeticholic acid trials): ALP <1.67× ULN with ≥15% reduction and normal bilirubin

— Approximately 30–40% of patients fail to achieve adequate response — these are candidates for second-line therapy

— Step 1: Confirm diagnosis → start UDCA 13–15 mg/kg/day in all patients regardless of stage

— Step 2: Reassess biochemistry at 6 and 12 months

— Step 3: If inadequate response → add obeticholic acid (if non-cirrhotic or Child–Pugh A) or a fibrate (off-label bezafibrate/fenofibrate)

— Step 4: Address symptoms (pruritus, sicca, fatigue) independently of disease-modifying therapy

— Step 5: Stage-based surveillance — varices, HCC, bone, fat-soluble vitamins

— Inadequate response to UDCA at 12 months

— Bilirubin progressively rising or >2 mg/dL

— Any decompensation (ascites, encephalopathy, variceal bleed)

— MELD ≥15 — early transplant referral

— Intractable pruritus refractory to medical therapy (transplant indication independent of MELD)

Board pearl: All PBC patients get UDCA, regardless of stage or symptoms — it is the only intervention proven to improve transplant-free survival and prevents progression to cirrhosis in the majority of responders. Delaying UDCA for "mild disease" is a wrong-answer trap on Step 3.

Goals of therapy in PBC:

Baseline risk stratification at diagnosis:

Biochemical response targets after 12 months of UDCA — the central decision point:

Stepwise management algorithm:

When to refer to hepatology/transplant center:

Pharmacotherapy — First-Line and Second-Line Regimens

— Dose: 13–15 mg/kg/day, divided BID or once daily with food

— Mechanism: hydrophilic bile acid that displaces hepatotoxic hydrophobic bile acids, stabilizes cholangiocyte membranes, exerts choleretic and immunomodulatory effects

— Onset of biochemical response: ALP/GGT begin falling within weeks; full effect at 6–12 months

— Adverse effects: generally well tolerated; weight gain (~3 kg), diarrhea, hair thinning

— Lifelong therapy — do not discontinue even if biochemistry normalizes

— Pregnancy category: safe (Category B); continue during pregnancy

— Indication: inadequate UDCA response after 12 months, or UDCA intolerance

— Dose: start 5 mg daily; titrate to 10 mg after 3 months if tolerated and inadequate response

— Contraindicated in decompensated cirrhosis (Child–Pugh B/C) — FDA boxed warning after reports of hepatic decompensation and death

— Major adverse effect: dose-dependent pruritus (up to 50%), HDL reduction

— Monitor LFTs at 1, 3, 6, 12 months; reduce dose if worsening

— Bezafibrate (BEZURSO trial): added to UDCA achieved complete biochemical response in ~30% vs 0% placebo

— Fenofibrate 145–200 mg daily is the U.S.-available alternative

— PPAR-α (and pan-PPAR for bezafibrate) agonism reduces bile acid synthesis

— Monitor for myalgia, creatinine rise, transaminitis

— Avoid in severe renal impairment and decompensated cirrhosis

— Pruritus stepwise: (1) cholestyramine 4 g before and after breakfast, separated from other meds by ≥4 hours; (2) rifampin 150–300 mg BID (monitor LFTs); (3) naltrexone 50 mg daily; (4) sertraline 75–100 mg

— Sicca: artificial tears, pilocarpine, cevimeline

— Osteoporosis: calcium 1200 mg, vitamin D 800–1000 IU; bisphosphonate (oral alendronate or IV zoledronic acid if varices)

Step 3 management: A patient on UDCA for 12 months with ALP still 2× ULN and normal bilirubin → add obeticholic acid 5 mg daily; if Child–Pugh B/C, use bezafibrate/fenofibrate instead — choosing OCA in decompensated cirrhosis is a high-yield wrong answer.

Ursodeoxycholic acid (UDCA) — first-line for ALL patients:

Obeticholic acid (OCA) — second-line FXR agonist:

Fibrates — off-label but increasingly used:

Emerging agents: elafibranor (PPAR α/δ) and seladelpar (PPAR-δ) recently approved for second-line use — improve ALP and pruritus.

Symptomatic pharmacotherapy:

Procedures, Endoscopy, and Transplantation

— PBC was historically a leading indication; incidence falling with UDCA

— Indications:

— MELD ≥15

— Decompensated cirrhosis (ascites, variceal bleed, encephalopathy, hepatorenal syndrome)

— Hepatocellular carcinoma within Milan criteria

— Intractable pruritus refractory to all medical therapy — a unique non-MELD indication; may warrant MELD exception points

— Severe hepatic osteodystrophy with fractures (less commonly accepted)

— Outcomes: 5-year survival ~80–85%; PBC has the best post-transplant survival among cholestatic indications

— Recurrence: PBC recurs in 20–30% by 10 years post-transplant; AMA often remains positive (not diagnostic of recurrence); post-transplant prophylactic UDCA reduces recurrence

— EGD for variceal screening: at diagnosis if cirrhosis or elastography >20 kPa, platelets <150k; otherwise per Baveno criteria

— Variceal band ligation for medium/large varices; nonselective beta-blocker (carvedilol/propranolol) for primary prophylaxis

— ERCP is not used diagnostically in PBC (intrahepatic small-duct disease); reserve for evaluating dominant strictures suggesting PSC or stones

— HCC surveillance: ultrasound ± AFP every 6 months in cirrhotic PBC (and possibly in men or those with advanced fibrosis even pre-cirrhosis)

— Therapeutic paracentesis for tense ascites; TIPS for refractory ascites or recurrent variceal bleeding in appropriate candidates

— Bisphosphonate therapy (oral preferred; IV zoledronic acid if esophageal varices or pill esophagitis risk)

— Vertebroplasty/kyphoplasty for symptomatic compression fractures

CCS pearl: For a PBC patient admitted with first variceal bleed, the CCS sequence is: IV access ×2, type and crossmatch, octreotide drip, IV ceftriaxone prophylaxis, urgent EGD with band ligation within 12 hours, transfuse to Hgb ~7, then transition to nonselective beta-blocker post-discharge and schedule surveillance EGD in 2–4 weeks.

Liver transplantation — the definitive intervention:

Endoscopic procedures:

Image-guided procedures:

Bone-directed interventions:

Plasmapheresis or molecular adsorbent recirculating system (MARS): rare salvage for intractable pruritus as bridge to transplant.

Special Populations — Elderly and Renal/Hepatic Impairment

— PBC at older onset tends to be less aggressive biochemically but more often diagnosed at advanced fibrotic stage due to delay

— Higher comorbidity burden — cardiovascular disease, osteoporosis baseline, polypharmacy

— UDCA dose unchanged (13–15 mg/kg); tolerability excellent

— Greater fall and fracture risk — prioritize early DEXA, vitamin D repletion, bisphosphonate

— Be vigilant for drug–drug interactions: cholestyramine binds levothyroxine, warfarin, digoxin, statins — separate dosing by ≥4 hours

— Cognitive screening before initiating rifampin or naltrexone for pruritus (sedation, confusion)

— Child–Pugh A: all therapies permissible

— Child–Pugh B/C: obeticholic acid is contraindicated (FDA boxed warning — hepatic decompensation/death)

— UDCA remains safe across all stages — dose may need slight reduction (10 mg/kg) if bilirubin >10

— Fibrates: caution in advanced cirrhosis; monitor LFTs and renal function

— Avoid hepatotoxins: acetaminophen <2 g/day max; avoid NSAIDs (renal + variceal bleed risk); avoid alcohol entirely

— Sedatives, opioids, benzodiazepines — start low or avoid (encephalopathy precipitant)

— Cholestyramine: safe but watch electrolyte derangement (hyperchloremic acidosis)

— Fibrates: dose-adjust; avoid fenofibrate if eGFR <30; bezafibrate similarly contraindicated

— Rifampin: hepatic metabolism, safe in CKD but interacts widely (CYP3A4 induction)

— Bisphosphonates: avoid oral if eGFR <35; IV zoledronic acid contraindicated below this threshold

— Hepatorenal syndrome in decompensated PBC — treat with albumin + terlipressin (or norepinephrine/octreotide+midodrine) and urgent transplant evaluation

— Cirrhotic PBC patients undergoing elective surgery: calculate MELD and Mayo Risk Score; MELD >15 confers high mortality

— Optimize coagulation, ascites, encephalopathy preoperatively

— Continue UDCA perioperatively; hold fibrates 24 hours; hold OCA if signs of decompensation

Board pearl: In a PBC patient with newly decompensated cirrhosis or jaundice on obeticholic acid, stop OCA immediately and refer for transplant evaluation — continuing OCA in Child–Pugh B/C is a recognized cause of preventable death.

Elderly patients (>65 years):

Hepatic impairment:

Renal impairment:

Perioperative considerations:

Special Populations — Pregnancy and Other Demographic Subgroups

— Fertility is generally preserved in non-cirrhotic disease

— UDCA is safe in pregnancy (Category B) and should be continued throughout — discontinuation risks flare and worsening cholestasis

— Pruritus often worsens in third trimester due to physiologic cholestasis of pregnancy superimposed on PBC; UDCA dose may be increased to 20–25 mg/kg

— Avoid in pregnancy: obeticholic acid (insufficient data), fibrates (animal teratogenicity), rifampin (vitamin K-dependent bleeding risk near term), methotrexate, mycophenolate

— Safe pruritus options: UDCA up-titration, cholestyramine, topical emollients; antihistamines (diphenhydramine, loratadine) for symptomatic relief

— Check vitamin K status near delivery; supplement to prevent neonatal hemorrhagic disease

— Cirrhotic patients: pre-pregnancy EGD for varices; if present, band-ligate or use beta-blockers (propranolol preferred); avoid pregnancy if MELD >10 ideally

— Mode of delivery — vaginal unless obstetric indication; if varices present, consider assisted second stage to reduce Valsalva

— UDCA compatible with breastfeeding (minimal excretion)

— Cholestyramine safe; rifampin enters milk — avoid if possible

— Fibrates: avoid

— Extremely rare — true pediatric PBC is exceptional; cholestatic disease in children is more likely PSC, biliary atresia, Alagille, PFIC, autoimmune sclerosing cholangitis

— Suspicion of PBC in a child mandates expert pediatric hepatology referral

— ~10% of cases; historically thought to have worse prognosis with higher HCC risk and later diagnosis

— Lower threshold for HCC surveillance even pre-cirrhosis

— More likely to be AMA-negative — broader autoantibody panel warranted

— Add corticosteroids (budesonide if non-cirrhotic; prednisone if cirrhotic) ± azathioprine to UDCA

— Higher transplant rate; closer monitoring

Step 3 management: A pregnant patient with known PBC and worsening third-trimester pruritus → continue UDCA, consider dose increase to 20 mg/kg, add cholestyramine, monitor bile acids and LFTs, and arrange delivery planning with vitamin K supplementation; never stop UDCA "because she is pregnant."

Pregnancy and PBC:

Breastfeeding:

Pediatric PBC:

Male patients with PBC:

Overlap-syndrome patients (PBC–AIH overlap):

Complications and Adverse Outcomes

— Cirrhosis and portal hypertension — ascites, varices, splenomegaly, encephalopathy

— Hepatocellular carcinoma — risk is ~3–5% in cirrhotic PBC; higher in men and inadequate UDCA responders; 6-month US ± AFP surveillance is standard once cirrhosis established

— Hepatic decompensation — progressive jaundice (bilirubin >2 = inflection point on Mayo Risk Score)

— Portopulmonary hypertension and hepatopulmonary syndrome — late complications

— Osteoporosis in 20–40%; osteomalacia rarer

— Multifactorial: vitamin D malabsorption, low IGF-1, cholestasis-induced osteoblast dysfunction, post-menopausal status, corticosteroid use in overlap

— Fragility vertebral and hip fractures

— DEXA at diagnosis and every 2 years; treat with calcium, vitamin D, bisphosphonates per FRAX/T-score

— Vitamin A: night blindness, xerophthalmia

— Vitamin D: osteomalacia, secondary hyperparathyroidism

— Vitamin E: ataxia, peripheral neuropathy, hemolysis

— Vitamin K: elevated INR, bleeding

— Check levels annually once bilirubin >2; supplement empirically in advanced disease

— Striking hypercholesterolemia (LDL or lipoprotein-X)

— Statins are safe in PBC despite cholestatic LFTs — treat per ASCVD risk; do not withhold based on ALP

— Sjögren (30–50%): dry eyes/mouth, dental caries, lymphoma risk

— Autoimmune thyroid disease (20%): screen TSH annually

— Celiac disease (~5%): test if iron deficiency, diarrhea, weight loss

— Renal tubular acidosis (distal type 1), interstitial nephritis

— Asymptomatic UTIs more common (associated with disease pathogenesis)

— Increased incidence of non-Hodgkin lymphoma (especially with Sjögren overlap)

— OCA-induced pruritus and hepatic decompensation in advanced disease

— Fibrate-induced myopathy, transaminitis, creatinine rise

— Bisphosphonate esophagitis (avoid if varices)

Board pearl: Hypercholesterolemia in PBC is not an automatic statin indication — base treatment on ASCVD 10-year risk, not LDL alone; lipoprotein-X (the dominant lipoparticle in cholestasis) is not atherogenic and partially explains the paradoxical lack of cardiovascular excess.

Hepatic complications:

Metabolic bone disease (hepatic osteodystrophy):

Fat-soluble vitamin deficiencies (advanced cholestasis):

Lipid abnormalities:

Coexisting autoimmune complications:

Other:

Treatment-related adverse outcomes:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— All newly diagnosed PBC patients should establish hepatology care

— Inadequate biochemical response to UDCA at 12 months

— AMA-negative cholestasis requiring biopsy

— Suspected overlap syndrome (high IgG, ALT >5× ULN)

— Pregnancy planning or active pregnancy

— Pre-transplant evaluation when MELD ≥15 or first decompensation

— New decompensation: ascites requiring large-volume paracentesis, encephalopathy, GI bleeding

— Spontaneous bacterial peritonitis (SBP): ascitic PMN >250 — admit, third-generation cephalosporin (ceftriaxone), IV albumin (1.5 g/kg day 1, 1 g/kg day 3)

— Variceal hemorrhage: ICU-level care

— Acute kidney injury suggestive of hepatorenal syndrome

— Severe intractable pruritus with suicidal ideation

— Acute cholangitis (uncommon in pure PBC but consider if RUQ pain + fever + jaundice)

— Hemodynamically unstable variceal bleed

— Grade 3–4 hepatic encephalopathy or airway compromise

— Hepatorenal syndrome type 1 (rapid creatinine doubling) requiring vasopressors

— Sepsis with cirrhosis (high mortality, low threshold for ICU and broad-spectrum antibiotics)

— Acute-on-chronic liver failure (ACLF) — calculate CLIF-SOFA; consider transplant center transfer

— Transplant surgery: MELD ≥15, intractable pruritus, HCC within Milan

— Interventional radiology: TIPS for refractory ascites or bleeding

— GI/endoscopy: variceal screening and banding

— Rheumatology: for sicca symptoms requiring systemic therapy

— Endocrinology: brittle thyroid disease, severe osteoporosis

— Palliative care: for advanced disease, intractable symptoms, transplant-ineligible patients

— At discharge after first decompensation: medication reconciliation (often new diuretics, lactulose, rifaximin, beta-blocker), follow-up in 1–2 weeks, surveillance EGD within 2–4 weeks if post-bleed

— Clear communication to PCP of MELD trajectory and transplant referral status

CCS pearl: PBC patient with cirrhosis admitted with ascites and fever — immediately diagnostic paracentesis before antibiotics; if PMN ≥250, start ceftriaxone 2 g IV daily + albumin 1.5 g/kg, hold beta-blockers if hypotensive, and place transplant referral in parallel.

Indications for hepatology consultation (outpatient):

Indications for inpatient admission:

ICU triage criteria:

Specialty consults in parallel:

Transitions of care — Step 3 emphasis:

Key Differentials — Other Cholestatic and Autoimmune Liver Diseases

— Male predominance, mean age ~40

— Strong association with IBD (ulcerative colitis in ~70%)

— MRCP: multifocal strictures and beading of intra- and extrahepatic ducts

— p-ANCA positive in 70%; AMA typically negative

— Markedly elevated cholangiocarcinoma risk (10–15% lifetime)

— No effective medical therapy; UDCA does not improve survival and high-dose UDCA may worsen outcomes

— Treatment: ERCP for dominant strictures, transplant for advanced disease

— Hepatocellular pattern: ALT/AST >>ALP

— ANA, ASMA, anti-LKM-1, anti-SLA positive; elevated IgG

— Biopsy: interface hepatitis with plasma cells

— Treatment: prednisone + azathioprine (or budesonide)

— PBC–AIH overlap treated with combined UDCA + immunosuppression

— Older men, painless jaundice, often with autoimmune pancreatitis

— Elevated serum IgG4

— Responsive to corticosteroids — important to distinguish from PSC

— Chronic biliary obstruction (stricture, stones, post-surgical)

— Imaging shows ductal dilation — distinguishes from PBC

— Treat underlying obstruction

— Estrogens, anabolic steroids, amoxicillin-clavulanate, sulfonamides, chlorpromazine, herbals (kava, green tea extract)

— AMA negative; resolves with discontinuation; biopsy shows bland cholestasis

— Idiopathic adulthood ductopenia, sarcoidosis-related, post-transplant rejection

— Biopsy shows ductopenia without classic PBC features; AMA negative

— Sarcoidosis, TB, brucellosis, drug-induced

— Sarcoid: ACE elevated, hilar lymphadenopathy, non-caseating granulomas; AMA negative

— PBC granulomas are florid duct lesions; sarcoid granulomas are randomly distributed

Key distinction: PBC vs PSC — PBC is the female, AMA-positive, small-duct, ultrasound-normal disease responsive to UDCA; PSC is the male, p-ANCA-positive, large-duct beaded-MRCP, IBD-associated disease unresponsive to UDCA and with cholangiocarcinoma risk requiring annual MRCP + CA 19-9 surveillance.

Primary sclerosing cholangitis (PSC):

Autoimmune hepatitis (AIH):

IgG4-related sclerosing cholangitis:

Secondary biliary cholangitis:

Drug-induced cholestasis:

Vanishing bile duct syndromes:

Granulomatous hepatitis:

Key Differentials — Other-Category Causes of Cholestasis

— Viral hepatitis (especially HCV, HEV): check serologies; pattern usually hepatocellular but can be mixed

— Alcohol-associated liver disease: AST:ALT >2, history of intake, GGT elevated; may have cholestatic features in alcoholic hepatitis

— NAFLD/MASLD: mild ALT > ALP elevation, metabolic syndrome features; ultrasound shows steatosis

— Wilson disease: young patient with neuropsychiatric features, low ceruloplasmin, low ALP-to-bilirubin ratio (<4) in fulminant presentation, Kayser-Fleischer rings

— Alpha-1 antitrypsin deficiency: check phenotype; pulmonary and hepatic manifestations

— Hemochromatosis: transferrin saturation >45%, ferritin elevated; HFE mutation

— Sarcoidosis: non-caseating granulomas, hilar adenopathy, elevated ACE, hypercalcemia

— Amyloidosis: organomegaly with markedly elevated ALP, often with proteinuria; fat pad or hepatic biopsy with Congo red

— Lymphoma/leukemia hepatic infiltration: B-symptoms, LDH elevation

— Tuberculosis of liver: in endemic areas or immunocompromised

— Choledocholithiasis: RUQ pain, fluctuating jaundice, ductal dilation on US

— Pancreatic head malignancy: painless jaundice, Courvoisier sign, weight loss, CA 19-9 elevated

— Mirizzi syndrome: stone in cystic duct compressing CBD

— Cholangiocarcinoma: progressive jaundice, weight loss, CA 19-9, MRCP for strictures

— All show ductal dilation on imaging — the key distinguishing feature from PBC

— Benign recurrent intrahepatic cholestasis (BRIC) and progressive familial intrahepatic cholestasis (PFIC) — younger patients, episodic or progressive cholestasis, ATP8B1/ABCB11/ABCB4 mutations

— Dubin-Johnson and Rotor: conjugated hyperbilirubinemia without ALP elevation — distinguishing them is straightforward

— Gilbert syndrome: unconjugated, isolated bilirubin elevation; not cholestatic

— Thyroid disease (severe hypothyroidism can elevate ALP via bone/liver)

— Adrenal insufficiency (mild LFT abnormalities)

Board pearl: First question to ask in any cholestatic pattern: "Are the bile ducts dilated on ultrasound?" Dilation → extrahepatic obstruction → MRCP/ERCP path. No dilation → intrahepatic cholestasis → autoantibody and biopsy path (PBC, PSC small-duct variant, drug, infiltrative).

Hepatocellular causes mimicking cholestasis:

Infiltrative diseases:

Extrahepatic biliary obstruction:

Functional/genetic cholestatic disorders:

Endocrine and infiltrative metabolic:

Long-Term Plan, Secondary Prevention, and Discharge Medications

— UDCA 13–15 mg/kg/day indefinitely — never discontinue

— Add second-line agent (OCA, fibrate, or PPAR agonist) for inadequate responders

— Reassess response annually with ALP, bilirubin, albumin, platelets

— Hepatitis A and B (if non-immune) — full series

— Pneumococcal (PCV15/20 then PPSV23 per ACIP)

— Annual influenza

— COVID-19 per current schedule

— Tdap booster every 10 years

— Zoster (Shingrix) in adults ≥50

— Avoid live vaccines if on immunosuppression for AIH overlap

— Calcium 1000–1200 mg/day (diet preferred) and vitamin D 800–1000 IU

— DEXA every 2 years; bisphosphonate if T-score ≤-2.5 or fragility fracture

— Weight-bearing exercise; smoking cessation; limit alcohol

— Statin if 10-year ASCVD risk ≥7.5–10% per ACC/AHA — PBC is not a contraindication

— Manage diabetes and hypertension to standard targets

— Smoking cessation (also a PBC risk factor)

— HCC ultrasound ± AFP every 6 months in cirrhotic PBC

— EGD for varices: at diagnosis if cirrhotic; repeat 2–3 years if no varices, 1–2 years if small varices

— DEXA every 2 years

— TSH annually; check celiac serology if symptoms

— Fat-soluble vitamins annually when bilirubin >2

— Hepatotoxic medications (acetaminophen >2 g/day, methotrexate without monitoring, amiodarone)

— NSAIDs in cirrhosis (renal and bleeding risk)

— Alcohol — complete abstinence preferred in advanced disease

— Sedatives, opioids in advanced disease (encephalopathy precipitants)

— Lifelong nature of disease and therapy

— Symptom diaries for pruritus and fatigue

— Recognition of decompensation (abdominal swelling, confusion, GI bleeding)

— Family screening: first-degree relatives of women — check ALP and AMA if elevated

Step 3 management: At every PBC follow-up visit, document UDCA adherence, biochemical response (ALP and bilirubin trend), surveillance status (EGD, DEXA, HCC US), vaccination uptake, and pruritus/fatigue scores — a structured checklist matches the value-based care emphasis of Step 3.

Lifelong disease-modifying therapy:

Vaccinations — essential at diagnosis:

Bone health:

Cardiovascular and metabolic:

Surveillance schedule:

Medications to avoid or use cautiously:

Patient education:

Follow-Up, Monitoring Parameters, and Counseling

— Newly diagnosed: hepatology evaluation, labs at 3 and 6 months after starting UDCA

— 12-month biochemical response assessment — pivotal decision point

— Stable, biochemically responsive: every 6–12 months

— Cirrhotic or inadequate responders: every 3–6 months

— Post-transplant: per transplant center protocol, with lifelong UDCA prophylaxis

— CBC (platelets — portal hypertension marker)

— CMP (ALP, AST, ALT, bilirubin, albumin, creatinine)

— INR if advanced disease

— TSH annually

— IgM, AMA titer not routinely repeated

— Lipid panel annually

— Fat-soluble vitamins if bilirubin >2 or symptomatic

— Calcium, phosphate, 25-OH vitamin D annually

— Liver elastography every 2–3 years to track fibrosis

— Ultrasound q6 months if cirrhotic (HCC)

— DEXA every 2 years

— EGD per variceal surveillance schedule

— Pruritus: ask at every visit; escalate stepwise (cholestyramine → rifampin → naltrexone → sertraline)

— Fatigue: assess functional impact; screen for depression, anemia, thyroid disease, sleep apnea (often comorbid)

— Sicca: ophthalmology and dental every 6–12 months; pilocarpine if symptomatic

— Cognitive/encephalopathy: Stroop or animal naming test in advanced disease

— Alcohol cessation — emphasize at every visit

— Smoking cessation — accelerates fibrosis

— Weight optimization — coexisting MASLD common

— Aerobic exercise improves fatigue and bone health

— Sun protection (chronic itching/scratching, photosensitivity from some PBC drugs)

— Mental health — depression and anxiety prevalent; refer for CBT, support groups

— Sexual health — sicca-related dyspareunia common; address openly

— Driving and occupational considerations if encephalopathy emerges

— 10× risk in first-degree female relatives — screen with ALP if symptoms or annually after age 40

— Reassess MELD every 3–6 months once cirrhosis established

— Early listing improves outcomes — do not wait for decompensation

Board pearl: A PBC patient with ALP normalized on UDCA but persistent disabling fatigue — biochemical response does not correlate with fatigue. Workup includes TSH, ferritin/iron studies, B12, depression screen, and sleep study before attributing to PBC alone. There is no proven pharmacotherapy for PBC fatigue.

Visit cadence:

Laboratory monitoring at each visit:

Imaging and procedural follow-up:

Symptom-targeted monitoring:

Counseling and rehabilitation:

Family and genetic counseling:

Transplant longitudinal planning:

Ethical, Legal, and Patient Safety Considerations

— Obeticholic acid: explicitly discuss FDA boxed warning of hepatic decompensation/death in advanced disease; document Child–Pugh assessment before initiation

— Liver biopsy: review bleeding, pneumothorax, bile leak; consider transjugular approach if coagulopathic or ascites present

— Liver transplantation: comprehensive discussion of waiting-list mortality, donor options (deceased vs living donor), recurrence (~20–30%), lifelong immunosuppression, malignancy risk

— Discharge after decompensation is the highest-risk transition; 30-day readmission rates approach 30%

— Medication reconciliation must address: new diuretics (spironolactone, furosemide), lactulose dosing to 3 BMs/day, rifaximin, beta-blockers, antibiotics for SBP prophylaxis

— Ensure outpatient labs at 1–2 weeks post-discharge (electrolytes, creatinine, INR)

— Communicate transplant evaluation status explicitly to PCP and patient

— Use teach-back method for diuretic adjustment, signs of encephalopathy, when to return

— Suspected medication-induced liver injury (DILI) should be reported to FDA MedWatch

— Hepatitis A/B/C and TB are reportable to public health

— Document driving safety counseling in patients with hepatic encephalopathy — some states mandate physician reporting of cognitive impairment

— Hepatic encephalopathy affects decision-making capacity; assess at each major treatment decision

— Advance directives and goals-of-care discussion appropriate when MELD ≥15 or transplant-ineligible

— OCA and PPAR agonists are costly — engage social work and pharmacy benefits early

— Transplant listing disparities (gender, race, insurance) — advocate actively for eligible patients

— Rural patients need coordinated travel for transplant evaluation

— Drug–drug interaction screening: cholestyramine binds many oral medications (separate by 4 hours)

— Rifampin: CYP3A4 induction reduces efficacy of oral contraceptives, warfarin, statins, anti-rejection agents — counsel and adjust

— Monitor for opioid-naloxone confusion with naltrexone use

— For patients ineligible for or declining transplant, integrate palliative care early

— Symptom-focused management of pruritus, ascites, encephalopathy

— Hospice referral when MELD progressive without transplant option

Step 3 management: Before starting rifampin for refractory PBC pruritus, counsel the patient on (1) hepatotoxicity monitoring (LFTs at 6 and 12 weeks), (2) orange discoloration of urine/tears (contact lens staining), (3) reduced contraceptive efficacy requiring barrier method, and (4) interaction with warfarin and tacrolimus — document this teaching to satisfy informed-consent and safety standards.

Informed consent considerations:

Transitions of care — Step 3 high-yield safety topic:

Mandatory and recommended reporting:

Capacity and decision-making:

Equity and access:

Patient safety in pharmacotherapy:

End-of-life and palliative considerations:

High-Yield Associations and Rapid-Fire Clinical Facts

— UDCA 13–15 mg/kg/day for everyone

— Obeticholic acid second-line (avoid in Child–Pugh B/C)

— Fibrates (bezafibrate, fenofibrate) off-label second-line

— Elafibranor and seladelpar newer PPAR-targeted options

— PBC: Perimenopausal woman, Bile duct destruction (small), Cholesterol high — AMA+, ultrasound normal

— PSC: PANCA, Strictures (large duct beading), Colitis (UC) — male, MRCP abnormal

Board pearl: When a middle-aged woman has elevated ALP and fatigue, the first three orders are simultaneously AMA, IgM level, and abdominal ultrasound — these three resolve over 90% of diagnostic uncertainty.

The "9:1" disease: Female-to-male ratio approximately 9:1; peak age 40–60.

AMA is the antibody: Anti-mitochondrial antibody (M2 subtype, against PDC-E2) — sensitivity ~95%, specificity >95%. AMA can precede disease by years and persists after transplant.

AMA-negative PBC (~5%): check anti-sp100 and anti-gp210; gp210 = worse prognosis.

Classic biochemical signature: Disproportionate ALP and GGT elevation with relatively preserved ALT/AST and bilirubin (early disease). Elevated IgM is characteristic.

Diagnostic triad without biopsy: ALP >1.5× ULN + AMA ≥1:40 + compatible imaging.

Treatment universals:

Pruritus ladder: cholestyramine → rifampin → naltrexone → sertraline → MARS/transplant.

Common autoimmune comorbidities: Sjögren (50%), autoimmune thyroid (20%), Raynaud, CREST, celiac, RA.

Hepatic osteodystrophy: Osteoporosis in 20–40% — DEXA at diagnosis.

Lipoprotein-X: Striking hypercholesterolemia in cholestasis; not atherogenic — statin decisions by ASCVD risk.

Histology buzzword: "Florid duct lesion" — granulomatous lymphocytic destruction of interlobular bile ducts.

PBC vs PSC mnemonic:

Mayo Risk Score variables: age, bilirubin, albumin, INR, edema/diuretic use — predicts transplant-free survival.

GLOBE and UK-PBC scores: modern prognostic tools used after 1 year of UDCA.

POISE criteria: ALP <1.67× ULN with ≥15% drop and normal bilirubin = adequate response.

Pregnancy: UDCA safe and continued; avoid OCA, fibrates, rifampin.

Transplant uniqueness: Intractable pruritus is a transplant indication independent of MELD.

Recurrence post-transplant: 20–30% by 10 years; prophylactic UDCA reduces recurrence.

HCC surveillance: US ± AFP every 6 months in cirrhotic PBC.

Avoid: alcohol, hepatotoxic drugs, live vaccines if immunosuppressed for overlap.

Board Question Stem Patterns

"A 52-year-old woman with hypothyroidism presents for routine exam. Asymptomatic. ALP 380, GGT 250, ALT 45, bilirubin 0.9. Ultrasound normal. AMA 1:160. Next step?"

— Answer: Start UDCA 13–15 mg/kg/day. No biopsy needed (triad met).

— Distractor: "Liver biopsy" — wrong because AMA+ with cholestatic labs + normal imaging = sufficient diagnosis.

"55-year-old woman on UDCA for 14 months. ALP still 2.5× ULN, bilirubin normal, Child–Pugh A. Next step?"

— Answer: Add obeticholic acid 5 mg daily. Alternative: bezafibrate/fenofibrate.

— Distractor: "Increase UDCA dose" — UDCA dose is already weight-based; escalating doesn't help.

"Patient with PBC, cirrhosis, ascites, MELD 18, ALP 2× ULN despite UDCA. Best next step?"

— Answer: Refer for transplant evaluation; do NOT start OCA (boxed warning in decompensated disease).

— Distractor: "Start obeticholic acid" — wrong answer here.

"PBC patient with disabling itching despite UDCA. First-line pruritus treatment?"

— Answer: Cholestyramine 4 g before and after breakfast.

— Second: rifampin. Third: naltrexone. Fourth: sertraline.

"45-year-old woman, ALP 4× ULN for 8 months, AMA negative. Next step?"

— Answer: Anti-sp100 and anti-gp210; if negative, liver biopsy.

"PBC patient with ALT 6× ULN, IgG elevated, ASMA positive. Treatment?"

— Answer: Add corticosteroid (budesonide if non-cirrhotic) ± azathioprine to UDCA.

"Pregnant patient with PBC, worsening third-trimester pruritus. Management?"

— Answer: Continue/increase UDCA; add cholestyramine; vitamin K near delivery. Avoid OCA, fibrates, rifampin.

"PBC patient with MELD 12 but daily intractable pruritus despite all medical therapies, suicidal ideation. Next step?"

— Answer: Transplant referral. Pruritus = MELD-exception indication.

"Cirrhotic PBC patient — what surveillance program?"

— Answer: HCC US ± AFP q6 months; EGD per variceal protocol; DEXA q2 years.

"PBC patient with LDL 220, 10-year ASCVD risk 5%. Start statin?"

— Answer: No — base decision on ASCVD risk, not LDL; lipoprotein-X is non-atherogenic.

"Young man with cholestatic labs, ulcerative colitis, beaded ducts on MRCP."

— Answer: PSC, not PBC. UDCA not recommended.

Step 3 management: Recognize that Step 3 PBC stems frequently test the 12-month decision point — whether the patient has achieved biochemical response — because that single inflection point drives the entire downstream management algorithm.

Stem 1 — The classic incidental finding:

Stem 2 — The inadequate responder:

Stem 3 — The OCA contraindication trap:

Stem 4 — The pruritus ladder:

Stem 5 — The AMA-negative variant:

Stem 6 — The overlap syndrome:

Stem 7 — The pregnancy question:

Stem 8 — The transplant indication:

Stem 9 — The surveillance question:

Stem 10 — The hypercholesterolemia trap:

Stem 11 — The differential:

One-Line Recap

Primary biliary cholangitis is a chronic, AMA-positive, female-predominant autoimmune cholestatic liver disease diagnosed by ALP elevation + positive antibody + normal imaging, treated lifelong with weight-based ursodeoxycholic acid, escalated to obeticholic acid or fibrates for inadequate 12-month biochemical responders, and surveilled long-term for cirrhosis, varices, hepatocellular carcinoma, osteoporosis, and treatment-refractory pruritus that itself can be a transplant indication.

Board pearl: The single highest-yield Step 3 inflection point in PBC is the 12-month biochemical response assessment on UDCA — it determines who continues monotherapy, who escalates to second-line agents, who needs transplant referral, and ultimately predicts long-term survival better than any baseline staging variable.

Diagnose: Middle-aged woman + ALP >1.5× ULN for ≥6 months + AMA (or PBC-specific ANA) + normal/non-dilated ducts on US → diagnose PBC without biopsy; reserve biopsy for AMA-negative cases or suspected AIH overlap.

Treat universally with UDCA 13–15 mg/kg/day, reassess at 6 and 12 months using POISE/Paris II criteria; ~30–40% are inadequate responders who need second-line therapy — obeticholic acid (only if Child–Pugh A and no decompensation) or off-label fibrates (bezafibrate/fenofibrate), with newer PPAR agonists (elafibranor, seladelpar) emerging.

Manage symptoms and complications independently: stepwise pruritus ladder (cholestyramine → rifampin → naltrexone → sertraline); DEXA-driven bone protection with calcium, vitamin D, and bisphosphonates; HCC ultrasound every 6 months in cirrhotic patients; EGD-based variceal surveillance; vaccinate against HAV/HBV/pneumococcus/influenza; statin therapy guided by ASCVD risk not LDL.

Escalate and refer: any decompensation, MELD ≥15, or intractable pruritus → transplant evaluation; PBC has the best post-transplant survival among cholestatic indications, with 20–30% recurrence by 10 years mitigated by lifelong prophylactic UDCA.